Доступ предоставлен для: Guest
Critical Reviews™ in Oncogenesis
Главный редактор: Benjamin Bonavida (open in a new tab)

Выходит 4 номеров в год

ISSN Печать: 0893-9675

ISSN Онлайн: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Dopamine Receptors in Breast Cancer: Prevalence, Signaling, and Therapeutic Applications

Том 27, Выпуск 2, 2022, pp. 51-71
DOI: 10.1615/CritRevOncog.2022043641
Get accessDownload

Краткое описание

Breast cancer (BC) is the most common malignancy among women, with over one million cases occurring annually worldwide. Although therapies against estrogen receptors and HER2 have improved response rate and survival, patients with advanced disease, who are resistant to anti-hormonal therapy and/or to chemotherapy, have limited treatment options for reducing morbidity and mortality. These limitations provide major incentives for developing new, effective, and personalized therapeutic interventions. This review presents evidence on the involvement of dopamine (DA) and its type 1 receptors (D1R) in BC. DA is produced in multiple peripheral organs and is present in the systemic circulation in significant amounts. D1R is overexpressed in ~ 30% of BC cases and is associated with advanced disease and shortened patient survival. Activation of D1R, which signals via the cGMP/PKG pathway, results in apoptosis, inhibition of cell invasion, and increased chemosensitivity in multiple BC cell lines. Fenoldopam, a peripheral D1R agonist that does not penetrate the brain, dramatically suppressed tumor growth in mouse models with D1R-expressing BC xenografts. It is proposed that D1R should serve as a novel diagnostic/prognostic factor through the use of currently available D1R detection methods. Fenoldopam, which is FDA-approved to treat renal hypertension, could be repurposed as an effective therapeutic agent for patients with D1R-expressing tumors. Several drugs that interfere with the cGMP/PKG pathway and are approved for treating other diseases should also be considered as potential treatments for BC.

ЛИТЕРАТУРА
  1. Ben-Jonathan N. Dopamine: Endocrine and oncogenic functions. Boca Raton, FL: CRC Press; 2020.

  2. Rubi B, Maechler P. Minireview: New roles for peripheral dopamine on metabolic control and tumor growth: Let's seek the balance. Endocrinology. 2010;151(12):5570-81.

  3. Borcherding DC, Hugo ER, Idelman G, Richtand NW, Loftus J, Ben-Jonathan N. Dopamine receptors in human adipocytes: Expression and functions. PLoS One. 2011;6(9):e25537.

  4. Marengo FD, Cardenas AM. How does the stimulus define exocytosis in adrenal chromaffin cells? Pflugers Arch. 2018;470(1):155-67.

  5. Goldstein DS, Swoboda KJ, Miles JM, Coppack SW, Aneman A, Holmes C, Lamensdorf I, Eisenhofer G. Sources and physiological significance of plasma dopamine sulfate. J Clin Endocrinol Metab. 1999;84(7):2523-31.

  6. Naila A, Flint S, Fletcher G, Bremer P, Meerdink G. Control of biogenic amines in food-existing and emerging approaches. J Food Sci. 2010;75(7):R139-R50.

  7. Kawamura M, Schwartz JP, Nomura T, Kopin IJ, Goldstein DS, Huynh TT, Hooper DR, Harvey-White J, Eisenhofer G. Differential effects of chemical sympathectomy on expression and activity of tyrosine hydroxylase and levels of catecholamines and DOPA in peripheral tissues of rats. Neurochem Res. 1999;24(1):25-32.

  8. Strott CA. Sulfonation and molecular action. Endocr Rev. 2002;23(5):703-32.

  9. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: From structure to function. Physiol Rev. 1998;78(1):189-225.

  10. Park JY, Lee SY, Kim HR, Seo MD, Chung KY. Structural mechanism of GPCR-arrestin interaction: Recent breakthroughs. Arch Pharm Res. 2016;39(3):293-301.

  11. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182-217.

  12. Missale C, Fiorentini C, Collo G, Spano P. The neurobiology of dopamine receptors: Evolution from the dual concept to heterodimer complexes. J Recept Signal Transduct Res. 2010;30(5):347-54.

  13. Shaywitz AJ, Greenberg ME. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem. 1999;68:821-61.

  14. Belkhiri A, Zhu S, El-Rifai W. DARPP-32: From neurotransmission to cancer. Oncotarget. 2016;7(14):17631-40.

  15. Avanes A, Lenz G, Momand J. Darpp-32 and t-Darpp protein products of PPP1R1B: Old dogs with new tricks. Biochem Pharmacol. 2019;160:71-9.

  16. Ben-Jonathan N, Borcherding DC, Fox SR, Hugo ER. Activation of the cGMP/protein kinase G system in breast cancer by dopamine receptor-1. Cancer Drug Resistance. 2019;2:933-47.

  17. Sharma RK, Duda T. Membrane guanylate cyclase, a multimodal transduction machine: History, present, and future directions. Front Mol Neurosci. 2014;7:article 56.

  18. Wang X, Robinson PJ. Cyclic GMP-dependent protein kinase and cellular signaling in the nervous system. J Neurochem. 1997;68(2):443-56.

  19. Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, Ahmad F, Manganiello V, Stratakis CA. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev. 2014;35(2):195-233.

  20. Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A. Phosphodiesterase 5 inhibitors-drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr Pharm Des. 2006;12(27):3459-65.

  21. Zhu B, Strada SJ. The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr Top Med Chem. 2007;7(4):437-54.

  22. Scatena R, Martorana GE, Bottoni P, Botta G, Pastore P, Giardina B. An update on pharmacological approaches to neurodegenerative diseases. Expert Opin Investig Drugs. 2007;16(1):59-72.

  23. Strange PG. Antipsychotic drug action: Antagonism, inverse agonism or partial agonism. Trends Pharmacol Sci. 2008;29(6):314-21.

  24. Baumeister AA, Francis JL. Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci. 2002;11(3):265-77.

  25. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1081-90.

  26. Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry. 2002;47(1):27-38.

  27. Glickstein SB, Schmauss C. Dopamine receptor functions: Lessons from knockout mice [corrected]. Pharmacol Ther. 2001;91(1):63-83.

  28. Pardridge WM. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.

  29. Reddymasu SC, Soykan I, McCallum RW. Domperidone: Review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102(9):2036-45.

  30. Parkman HP, Mishra A, Jacobs M, Pathikonda M, Sachdeva P, Gaughan J, Krynetskiy E. Clinical response and side effects of metoclopramide: Associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012;46(6):494-503.

  31. Mathur VS, Swan SK, Lambrecht LJ, Anjum S, Fellmann J, McGuire D, Epstein M, Luther RR. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med. 1999;27(9):1832-7.

  32. Murphy MB, Murray C, Shorten GD. Fenoldopam: A selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001;345(21):1548-57.

  33. Borcherding DC, Tong W, Hugo ER, Barnard DF, Fox S, LaSance K, Shaughnessy E, Ben-Jonathan N. Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer. Oncogene. 2016;35(24):3103-13.

  34. Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancer incidence in first- and second-degree relatives of BRCA1 and BRCA2 mutation carriers. Oncologist. 2016;21(7):869-74.

  35. Schnitt SJ. Classification and prognosis of invasive breast cancer: From morphology to molecular taxonomy. Mod Pathol. 2010;23(Suppl 2):S60-S4.

  36. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008;34(4):378-90.

  37. Garcia-Aranda M, Redondo M. Immunotherapy: A challenge of breast cancer treatment. Cancers. 2019;11(12);1822-35.

  38. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24-33.

  39. Huang B, Warner M, Gustafsson JA. Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol. 2015;418 Pt 3:240-4.

  40. Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: Current status, possible mechanisms and overcoming strategies. Future Med Chem. 2015;7(12):1511-9.

  41. Jacobson EM, Hugo ER, Borcherding DC, Ben-Jonathan N. Prolactin in breast and prostate cancer: Molecular and genetic perspectives. Discov Med. 2011;11(59):315-24.

  42. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724-63.

  43. Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, Levadoux-Martin M, Lee JB, Giacomelli AO, Hassell JA, Fischer-Russell D, Trus MR, Foley R, Leber B, Xenocostas A, Brown ED, Collins TJ, Bhatia M. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012;149(6):1284-97.

  44. Yong L, Yao Y, Chen GS, Yan XX, Guo YC, Han MY, Xue JS, Jian WZ, Zhou TY. QAP14 suppresses breast cancer stemness and metastasis via activation of dopamine D1 receptor. Acta Pharmacol Sin. 2022; doi: 10.1038/s41401-021-00701-9. Online ahead of print.

  45. Gholipour N, Ohradanova-Repic A, Ahangari G. A novel report of MiR-4301 induces cell apoptosis by negatively regulating DRD2 expression in human breast cancer cells. J Cell Biochem. 2018;119(8):6408-17.

  46. Bakhtou H, Olfatbakhsh A, Deezagi A, Ahangari G. The expression of dopamine receptors gene and their potential role in targeting breast cancer cells with selective agonist and antagonist drugs. Could it be the novel insight to therapy? Curr Drug Discov Technol. 2019;16(2):184-97.

  47. Idirisinghe PK, Thike AA, Cheok PY, Tse GM, Lui PC, Fook-Chong S, Wong NS, Tan PH. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol. 2010;133(3):416-29.

  48. Pornour M, Ahangari G, Hejazi SH, Ahmadkhaniha HR, Akbari ME. Dopamine receptor gene (DRD1-DRD5) expression changes as stress factors associated with breast cancer. Asian Pac J Cancer Prev. 2014;15(23):10339-43.

  49. Belkhiri A, Dar AA, Peng DF, Razvi MH, Rinehart C, Arteaga CL, El-Rifai W. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells. Clin Cancer Res. 2008;14(14):4564-71.

  50. Christenson JL, Denny EC, Kane SE. t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib. Oncotarget. 2015;6(32):33134-45.

  51. Denny EC, Kane SE. t-Darpp promotes enhanced EGFR activation and new drug synergies in Her2-positive breast cancer cells. PLoS One. 2015;10(6):e0132267.

  52. Ji J, Sundquist K, Ning Y, Kendler KS, Sundquist J, Chen X. Incidence of cancer in patients with schizophrenia and their first-degree relatives: A population-based study in Sweden. Schizophr Bull. 2013;39(3):527-36.

  53. Fallahian F, Karami-Tehrani F, Salami S, Aghaei M. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J. 2011;278(18):3360-9.

  54. Sarkar C, Chakroborty D, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am J Physiol Heart Circ Physiol. 2004;287(4):H1554-H60.

  55. Goyette MA, Cusseddu R, Elkholi I, Abu-Thuraia A, El-Hachem N, Haibe-Kains B, Gratton JP, Cote JF. AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer. Oncotarget. 2019;10 (21):2055-67.

  56. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 1997;385(6617):634-6.

  57. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691-702.

  58. Bodei S, Arrighi N, Spano P, Sigala S. Should we be cautious on the use of commercially available antibodies to dopamine receptors? Naunyn Schmiedebergs Arch Pharmacol. 2009;379(4):413-5.

Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции Цены и условия подписки Begell House Контакты Language English 中文 Русский Português German French Spain